WAVEMAN · COMPANY

CTSO · Cytosorbents Corp

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

CTSO

Name: Cytosorbents Corp (CTSO) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Cytosorbents Corp

MEDICAL DEVICES · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · CIK 0001175151

C-SUITE BUYING · 2☆ WATCH

INSIDER NET · 180D

$148.9K

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

13F, latest reported quarter

REVENUE GROWTH

+4.1%

XBRL, annual

NET MARGIN

-22.1%

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net +$148.9K over 180 days

+$148.9K over 90 days

more than 82% of Medical Devices

CONGRESS

no member of Congress has reported trading it

FUNDS

20 funds added or opened last quarter

below 74% of Medical Devices

REVENUE

+4.1% year over year

below 61% of Medical Devices

MARGIN

-22.1% net margin

below 61% of Medical Devices

BUYBACKS

no share repurchases reported

SHORT

3.4% of shares outstanding short · 38.3 days to cover · settled 2026-07-31

more than 50% of Medical Devices

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN -59.6%

-59.6%12M

INSIDER BUY

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders are net buyers of their own stock.

The record shows a net $148.9K bought by insiders over 180 days, 20 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

TMO PEN ROK BLFS MTD SIBN WRBY ISRG TXG DXCM EW TMDX

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Cytosorbents Corp insiders bought a net $148.9K of stock across 48 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

MARIANI PETER J

Chief Financial Officer

BUY

2026-06-15

100,000.0

$44.0K

Chan Phillip P.

Chief Executive Officer

BUY

2026-06-15

10,333.0

$4.4K

Chan Phillip P.

Chief Executive Officer

BUY

2026-06-12

251,136.0

$100.5K

MARIANI PETER J

Chief Financial Officer

BUY

2024-12-13

20,000.0

$19.2K

MARIANI PETER J

Chief Financial Officer

BUY

2024-12-12

20,000.0

$17.8K

48 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 43 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

AVENIR CORP

5,189,218.0 sh

$1.9M

NEUBERGER BERMAN GROUP LLC

1,968,691.0 sh

$740.5K

VANGUARD CAPITAL MANAGEMENT LLC

1,914,063.0 sh

$715.9K

CM Management, LLC

1,476,500.0 sh

$552.2K

Skylands Capital, LLC

1,211,400.0 sh

$453.1K

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Neuberger Intrinsic Value Fund

$486.9K POSITION · AS OF 2026-02-28

0.0%

iShares Micro-Cap ETF

$82.4K POSITION · AS OF 2026-03-31

0.0%

1290 VT Micro Cap Portfolio

$6.4K POSITION · AS OF 2026-03-31

0.0%

Morgan Stanley Pathway Small-Mid Cap Equity ETF

$17.2K POSITION · AS OF 2026-02-28

0.0%

Fidelity Extended Market Index Fund

$222.7K POSITION · AS OF 2026-02-28

0.0%

VANGUARD EXTENDED MARKET INDEX FUND

$306.0K POSITION · AS OF 2026-03-31

0.0%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 7 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

0 ACTIVE

Not applicable

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$37.1M	$35.6M	$31.1M	$34.7M
GROSS PROFIT	$26.5M	$24.9M	$22.0M	$20.7M
OPERATING INCOME	$-14.7M	$-16.5M	$-31.9M	$-31.5M
NET INCOME	$-8.2M	$-20.7M	$-29.2M	$-32.8M
EPS (DILUTED)	-0.13	-0.38	-0.65	-0.75
OPERATING CASH FLOW	$-12.4M	$-14.4M	$-21.7M	$-28.2M
CASH	$6.2M	$3.3M	$14.1M	$22.1M
LONG-TERM DEBT	$16.7M	$14.0M	$2.5M	$5.0M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE